The Hidden Prevalence of Lupus in the U.S.
- 7 days ago
- 31 min read
Diagnostic Friction, COVID Pandemic Accelerated Autoimmune Pressure, and the Hidden Scale of Lupus
This paper is part of the CYNAERA Autoimmune Library, a growing resource, built to help redefine how Lupus is researched, diagnosed, counted and treated.
By Cynthia Adinig
Executive Summary
Lupus is a serious autoimmune disease and chronic inflammatory condition whose true U.S. population impact is likely significantly underestimated. Current federal prevalence estimates suggest that approximately 204,000 people in the United States meet strict classification criteria for systemic lupus erythematosus (SLE), while the Lupus Foundation of America estimates that approximately 1.5 million Americans live with a form of lupus (Izmirly et al., 2021; Lupus Foundation of America, 2025). These figures are often framed as contradictory, but they are more accurately understood as measuring different layers of lupus visibility. The CDC-funded estimate reflects patients captured within strict SLE classification systems, while the advocacy estimate reflects broader lupus-spectrum disease observed across clinical, familial, and community settings.
Lupus prevalence is difficult to measure because lupus is not a uniformly visible autoimmune disease. Lupus symptoms may fluctuate for years before patients meet full systemic lupus erythematosus classification criteria, and many patients experience delayed diagnosis, incomplete lupus presentations, overlap connective tissue disease, or multisystem inflammatory symptoms that remain fragmented across specialties (Tsokos, 2011; Kaul et al., 2016; Durcan et al., 2019). Patients frequently move between rheumatology, dermatology, nephrology, cardiology, neurology, allergy/immunology, and primary care before a unifying lupus diagnosis is recognized. This creates a large gap between biologically active lupus-spectrum disease and administratively visible lupus cases.
Research on lupus diagnostic delay reinforces the likelihood that lupus prevalence is substantially undercounted. A 2024 analysis found a median delay of approximately 47 months between first symptom onset and formal SLE diagnosis, demonstrating that diagnosis-based prevalence systems capture only part of the true lupus disease timeline (Mitchell et al., 2024). Similar visibility problems have been documented across other immune-mediated and infection-associated chronic conditions including ME/CFS, Lyme, dysautonomia, Sjögren’s disease, mast cell activation syndrome, and post-viral neuroimmune illness (Institute of Medicine, 2015; Wirth and Scheibenbogen, 2020). These conditions frequently involve fluctuating symptoms, delayed recognition, specialist-dependent classification, and incomplete biomarker visibility.
The COVID-19 pandemic further intensified concern regarding autoimmune disease prevalence and post-viral immune dysfunction. Large cohort studies and meta-analyses now support increased autoimmune disease risk following SARS-CoV-2 infection, including elevated risks for systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s disease, inflammatory bowel disease, vasculitis, and related connective tissue disorders (Chang et al., 2023; Wang et al., 2023; Gil et al., 2025). Long COVID research has also demonstrated substantial overlap with ME/CFS, dysautonomia, mast cell activation, endothelial dysfunction, and chronic neuroimmune activation, suggesting that post-infectious autoimmune pressure may continue influencing lupus-spectrum prevalence for years after the acute pandemic phase.
This paper integrates the CYNAERA Diagnostic Multiplier™ Model™ (DMM™) with the US-CCUC™ (U.S. Chronic Condition Undercount Correction) framework to model lupus prevalence beyond strict classification-based surveillance. DMM™ estimates the degree to which diagnostic friction, delayed recognition, fluctuating disease activity, specialist-dependent diagnosis, and incomplete lupus classification compress visible prevalence. US-CCUC™ extends this correction logic by incorporating post-infectious expansion pressure, healthcare visibility gaps, overlap autoimmune disease, and structurally undercounted populations into broader population impact modeling.
Using DMM™, US-CCUC™, federal prevalence anchors, advocacy estimates, lupus diagnostic delay research, and post-COVID autoimmune literature, this paper argues that the adjusted U.S. lupus-spectrum population impact is likely closer to 2.5 to 3.0 million people. This estimate is not intended to replace strict systemic lupus erythematosus surveillance counts. Rather, it is intended to model the broader lupus-spectrum population impact likely present when diagnostic invisibility, delayed recognition, overlap autoimmune disease, incomplete lupus classification, environmental load, reproductive immune stress, and post-COVID autoimmune activation are taken into account.
Why Lupus Is Commonly Underdiagnosed and Diagnosed Late
Lupus is not a static disease state captured cleanly at a single point in time. It is a chronic, relapsing autoimmune condition capable of affecting nearly every major organ system, including the skin, joints, kidneys, cardiovascular system, lungs, nervous system, and vascular networks. Disease activity may range from mild intermittent inflammatory symptoms to rapidly progressive multi-organ dysfunction requiring aggressive immunosuppression (Tsokos, 2011; Fanouriakis et al., 2021). The CDC notes that lupus can be difficult to diagnose because symptoms vary substantially between patients and often resemble those of other illnesses (CDC, 2024).
These characteristics create major challenges for prevalence prevalence systems. Traditional epidemiologic models function best when diseases possess relatively stable diagnostic characteristics, such as standardized screening pathways, persistently positive biomarkers, or highly visible structural pathology. Lupus frequently resists these assumptions. Serologic findings may fluctuate across time, organ involvement may emerge gradually, and patients may experience clinically significant immune dysfunction for years before satisfying formal classification criteria (Smolen et al., 2020; Pisetsky, 2023). Concerns regarding lupus underrecognition are not new. Epidemiologic studies have long noted substantial variability in lupus prevalence estimates depending on registry methodology, healthcare access, racial demographics, and case-definition strategy (Pons-Estel et al., 2010; Rees et al., 2017).
As a result, prevalence systems relying primarily on diagnosis codes, registry participation, insurance-linked healthcare engagement, or specialist-confirmed classification may systematically undercount true disease population impact. These systems capture individuals who successfully navigate the diagnostic pathway. They do not fully capture patients who remain undiagnosed, intermittently symptomatic, seronegative, uninsured, geographically isolated, or clinically fragmented across multiple specialties without a unifying diagnosis. Patients managed under adjacent labels such as inflammatory arthritis, chronic fatigue, nephropathy, connective tissue overlap syndromes, dysautonomia, dermatitis, fibromyalgia, or Sjögren’s-like illness may never appear within strict lupus prevalence systems despite experiencing substantial lupus-spectrum pathology (Durcan et al., 2019; Mitchell et al., 2024).
This distinction helps explain the substantial gap between the CDC-funded SLE estimate and the broader Lupus Foundation of America estimate. The CDC-funded meta-analysis estimated approximately 204,295 Americans living with SLE using American College of Rheumatology classification criteria and registry-confirmed prevalence systems methods (Izmirly et al., 2021). The same study found disproportionately elevated prevalence among Black females and American Indian/Alaska Native populations, reinforcing longstanding evidence that lupus population impact is not evenly distributed across demographic groups (Lim et al., 2014; Izmirly et al., 2021). In contrast, the Lupus Foundation of America continues to estimate that approximately 1.5 million Americans have a form of lupus, reflecting a broader lupus-spectrum framework not restricted solely to registry-confirmed SLE classification (Lupus Foundation of America, 2025).
The methodological implication is important. These figures are not directly competing estimates of the same phenomenon. They represent different layers of disease visibility. The federal estimate functions as a strict SLE prevalence systems floor, while the advocacy estimate functions as a broader lupus-spectrum population impact signal. CYNAERA’s prevalence modeling framework attempts to estimate the space between them.
CYNAERA’s Lupus Prevalence Framework: DMM™, COVID Autoimmune Pressure
Step 1. Establish the Broad Lupus population impact Anchor
CYNAERA begins with the Lupus Foundation of America’s estimate that approximately 1.5 million Americans have a form of lupus (Lupus Foundation of America, 2025). This estimate is used as the broad lupus-spectrum anchor because it extends beyond strict registry-confirmed systemic lupus erythematosus (SLE) prevalence systems and better reflects real-world clinical visibility. This anchor is intentionally broader than the CDC-funded strict SLE prevalence systems estimate of approximately 204,295 Americans meeting formal classification criteria (Izmirly et al., 2021). CYNAERA treats the CDC estimate as the strict prevalence systems floor rather than the total lupus-spectrum population impact.
Step 2. Apply Diagnostic Friction Correction Using DMM™
Lupus demonstrates elevated diagnostic friction across multiple DMM™ domains, including delayed diagnosis, specialist dependency, fluctuating serology, overlap connective tissue disease, and underrecognized subgroup population impact (Mitchell et al., 2024; Rees et al., 2017).
CYNAERA therefore applies a moderate-to-high diagnostic visibility adjustment:
DMM™ Domain | Estimated Contribution |
Stigma population impact | 0.05 |
Physician education gaps | 0.06 |
Diagnostic limitation population impact | 0.07 |
Specialist dependency | 0.06 |
Underrecognized subgroup population impact | 0.05 |
Late-detection bias | 0.08 |
Total Diagnostic Friction Load (DFL)
DFL = 0.05 + 0.06 + 0.07 + 0.06 + 0.05 + 0.08 = 0.37
Diagnostic Multiplier
DM = 1 + 0.37 = 1.37
Lupus Population Impact After DMM™ Correction
1.5 million × 1.37 = 2.055 million
This produces an estimated lupus-spectrum population impact of approximately 2.1 million people before post-COVID autoimmune adjustment.
Step 3. Apply COVID-Accelerated Autoimmune Pressure Adjustment
Large cohort studies and meta-analyses now support increased autoimmune disease risk following SARS-CoV-2 infection, including elevated risks for SLE, rheumatoid arthritis, Sjögren’s disease, inflammatory bowel disease, and related connective tissue disorders (Chang et al., 2023; Gil et al., 2025).
However, CYNAERA models lupus more conservatively than ME/CFS or dysautonomia because:
lupus conversion is more criteria-dependent
lupus requires evolving autoimmune pathology
formal SLE classification remains specialist-driven
Long COVID phenocopies ME/CFS/POTS more strongly than lupus
For this reason, CYNAERA applies a bounded COVID pandemic autoimmune pressure range of approximately:
1.05–1.40
Applied to the DMM™-corrected population impact:
Lower range: 2.055 million × 1.05 = 2.16 million
Upper range: 2.055 million × 1.40 = 2.88 million
The estimate is intentionally bounded and should not be interpreted as a claim that all affected individuals meet strict SLE classification criteria. Rather, it attempts to model the broader lupus-spectrum population impact likely present when diagnostic invisibility, delayed recognition, overlap autoimmune disease, fluctuating serology, post-viral immune activation, and modern prevalence systems limitations are considered simultaneously within a COVID impacted epidemiologic framework.
US-CCUC™ Cross-Condition Triangulation
US-CCUC™ (U.S. Chronic Condition Undercount Correction) is a CYNAERA prevalence correction framework used to estimate how much chronic illnesses may be undercounted within traditional prevalence systems systems. Federal prevalence systems estimates suggest that approximately 204,000 Americans meet strict systemic lupus erythematosus (SLE) classification criteria through registry-based prevalence systems methods (Izmirly et al., 2021). However, the Lupus Foundation of America estimates that approximately 1.5 million Americans have a form of lupus, reflecting a broader lupus-spectrum population impact extending beyond registry-confirmed SLE (Lupus Foundation of America, 2025).
Lupus demonstrates many of the same prevalence systems limitations observed across other high-friction chronic illnesses. Disease activity may fluctuate across years before formal classification occurs, while patients often move through multiple specialties prior to diagnosis. Serologic findings may evolve gradually, overlap connective tissue presentations are common, and diagnosis frequently depends on specialist access and longitudinal interpretation rather than a single definitive test (Tsokos, 2011; Kaul et al., 2016). Diagnostic delay studies further show that many patients remain biologically and clinically ill for years before formal SLE classification is reached (Mitchell et al., 2024).
COVID impact autoimmune research also supports moderate upward correction pressure. Multiple cohort studies and meta-analyses now demonstrate increased autoimmune disease risk following SARS-CoV-2 infection, including elevated risk for SLE, Sjögren’s disease, rheumatoid arthritis, inflammatory bowel disease, and related connective tissue disorders (Chang et al., 2023; Gil et al., 2025). However, lupus expansion appears more constrained than ME/CFS or dysautonomia because formal lupus conversion remains more dependent on evolving autoimmune pathology, serologic progression, and specialist-confirmed classification.
Worked Math Box — Lupus
Strict prevalence systems floor: 204,295 SLE cases
Broad lupus-spectrum anchor: 1.5 million Americans with a form of lupus
DMM™ correction:
1.5 million × 1.37 = 2.055 million
Post-COVID autoimmune pressure adjustment:
Low range:
2.055 million × 1.05 = 2.16 million
High range:
2.055 million × 1.40 = 2.88 million
Reported Corrected Range
Corrected lupus-spectrum population impact ≈ 2.1M–2.9M adults
Public CYNAERA estimate ≈ 2.5M–3.0M adults
Planning midpoint ≈ 2.5M adults
Expanded planning range ≈ 3.0M–3.4M adults
Final CYNAERA Lupus Estimate
Estimate Type | Estimated population impact |
Strict CDC SLE prevalence systems floor | ~204,000 |
LFA broad lupus anchor | ~1.5 million |
DMM™ corrected population impact | ~2.1 million |
DMM™ + post-COVID adjusted population impact | ~2.1M–2.9M |
CYNAERA midpoint estimate | ~2.5 million |
Expanded planning range | ~3.0M–3.4M |
Takeaway
Lupus appears substantially undercounted within strict prevalence systems. Post-COVID infection autoimmune activation likely increased lupus-spectrum population impact meaningfully, though less aggressively than ME/CFS or dysautonomia-spectrum illness. CYNAERA therefore places lupus within an intermediate post-pandemic correction category bounded between traditional autoimmune prevalence systems and high-expansion post-viral neuroimmune illness behavior
CYNAERA Lupus Prevalence Calibration by Race/Ethnicity (U.S.)
Strict SLE Diagnosis Rates vs CYNAERA Corrected Lupus-Spectrum Estimates
Group | Strict SLE Diagnosis Estimate | Approx. Percent | CYNAERA Visibility Interpretation | CYNAERA Corrected Lupus-Spectrum Range |
White women | ~64–85 per 100,000 | ~0.06–0.09% | Highest healthcare visibility and referral continuity, but incomplete lupus and overlap disease still missed | ~0.25–0.45% |
Black women | ~211–231 per 100,000 | ~0.21–0.23% | Strongest stereotype fit and clinician suspicion, but major structural compression from delayed care, nephritis-stage diagnosis, and cumulative load | ~0.55–0.95% |
Hispanic/Latine women | ~121–138 per 100,000 | ~0.12–0.14% | Elevated biologic signal with fragmented visibility from language, insurance, and continuity barriers | ~0.40–0.75% |
Asian/Pacific Islander women | ~84–91 per 100,000 | ~0.08–0.09% | Likely compressed by subgroup aggregation and lower stereotype centrality in U.S. lupus narratives | ~0.30–0.60% |
American Indian/Alaska Native women | ~271 per 100,000 | ~0.27% | Highest observed diagnosis prevalence with major geographic and specialty-access barriers | ~0.70–1.10% |
White men | ~9 per 100,000 | ~0.009% | Low stereotype fit because lupus is heavily coded as female | ~0.05–0.10% |
Black men | ~27 per 100,000 | ~0.027% | Higher biologic signal plus severe underrecognition due to gender mismatch | ~0.10–0.20% |
Hispanic/Latine men | ~18 per 100,000 | ~0.018% | Likely compressed by both gender and access barriers | ~0.08–0.16% |
Asian/Pacific Islander men | ~11 per 100,000 | ~0.011% | Likely compressed by subgroup aggregation and low male stereotype fit | ~0.06–0.12% |
American Indian/Alaska Native men | ~54 per 100,000 | ~0.054% | High observed prevalence plus likely undercapture in rural systems | ~0.15–0.30% |
CYNAERA Interpretation
The strict diagnosis estimates above reflect classified systemic lupus erythematosus (SLE), not the full lupus-spectrum population. CYNAERA corrected estimates incorporate:
diagnostic delay
incomplete lupus
overlap connective tissue disease
underrecognized male lupus
specialist-access barriers
lupus nephritis discovered late
post-COVID autoimmune activation pressure
and visibility compression across race, sex, geography, and healthcare access
The pattern suggests that lupus is:
genuinely more common in several non-White populations
but also structurally distorted by differences in diagnostic visibility, healthcare access, environmental load, and delayed recognition
The chart also supports a central CYNAERA principle:
Prevalence is shaped not only by biology, but by whether the healthcare system is trained, willing, and structurally able to recognize disease before severe deterioration occurs. Unlike ME/CFS or POTS, lupus already has moderate stereotype visibility in some populations of color. This means lupus likely requires a more moderate correction model than conditions that remain largely invisible in BIPOC populations.
Lessons From ME/CFS and Other Underdiagnosed Chronic Illnesses
The gap between the CDC-funded strict SLE estimate and the Lupus Foundation of America’s broader lupus estimate is substantial. Using the CDC estimate of approximately 204,295 Americans meeting formal SLE classification criteria and the LFA estimate of 1.5 million Americans with a form of lupus, the advocacy estimate is roughly 635% higher than the strict federal prevalence systems figure (Izmirly et al., 2021; Lupus Foundation of America, 2025). At first glance, this difference may appear implausibly large. However, the discrepancy becomes more understandable when viewed through the lens of diagnostic friction, classification methodology, and chronic illness visibility.
Importantly, these estimates are not measuring identical phenomena.
The CDC-funded estimate was derived from registry-based prevalence systems focused specifically on systemic lupus erythematosus using formal American College of Rheumatology classification criteria (Izmirly et al., 2021). The LFA estimate reflects a broader lupus-spectrum framing that includes forms of lupus extending beyond registry-confirmed SLE. These include cutaneous lupus, drug-induced lupus, incomplete lupus, overlap connective tissue disease, and patients carrying lupus diagnoses or lupus-spectrum clinical histories without necessarily appearing within formal SLE registries (Lupus Foundation of America, 2025). The difference therefore reflects not only disagreement about prevalence, but also disagreement about what constitutes measurable disease population impact.
This distinction is particularly important in immune-mediated illnesses characterized by delayed diagnosis and fluctuating disease expression. Lupus is not nationally reportable, is expensive to track, and often depends on specialist recognition for definitive classification. Patients may spend years moving through fragmented healthcare systems before formal diagnosis occurs, particularly during early or incomplete disease states (Durcan et al., 2019; Mitchell et al., 2024). Epidemiologic visibility therefore becomes partially dependent on healthcare access, specialist density, insurance status, referral timing, geographic location, and provider familiarity with evolving autoimmune presentations.
Historical lupus epidemiology literature has repeatedly documented substantial variability in prevalence estimates depending on methodology, demographic composition, and case ascertainment strategy. International reviews have shown that lupus prevalence estimates differ widely across populations, with particularly elevated disease population impact observed among Black, Hispanic, Asian, and Indigenous populations (Pons-Estel et al., 2010; Rees et al., 2017). Even within the United States, registry studies have demonstrated marked variation by race, sex, and geography, suggesting that prevalence systems capture is shaped not only by biology, but also by healthcare-system visibility (Lim et al., 2014; Izmirly et al., 2021).
The COVID-19 era provides additional context for understanding why large prevalence gaps may emerge in chronic immune-mediated illnesses. Prior to the pandemic, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) was widely regarded as a relatively rare condition despite decades of evidence suggesting substantial underdiagnosis. Federal prevalence discussions commonly referenced estimates ranging from several hundred thousand to approximately 2.5 million Americans. More recent CDC materials now estimate that as many as 3.3 million adults in the United States may have ME/CFS and acknowledge that most affected individuals remain undiagnosed (CDC, 2024; National Academy of Medicine, 2015). This shift does not prove that lupus prevalence must rise proportionally. However, it demonstrates that illnesses characterized by fluctuating symptoms, specialist-dependent diagnosis, and inconsistent visibility can remain substantially compressed within official prevalence systems for years before broader population impact becomes more widely recognized.
This historical precedent matters because it reframes how prevalence discrepancies should be interpreted. Large differences between federal prevalence systems estimates, advocacy estimates, and corrected population impact models are not necessarily evidence of exaggeration. In some chronic illnesses, they may instead reflect the distance between visible disease and true disease population impact. CYNAERA’s DMM™ framework treats this distance as epidemiologically meaningful rather than statistically inconvenient. The question is not simply whether one number is “correct.” The more important question is what forms of disease visibility each number captures, and what populations remain hidden between them.
Recent shifts in ME/CFS prevalence estimates provide an important comparator for lupus prevalence modeling because they show how high-friction chronic illnesses can remain compressed in official systems for years before prevalence systems methods begin catching up. Historically, U.S. ME/CFS population impact was commonly framed within a range of approximately 836,000 to 2.5 million people, while more recent CDC materials estimate that as many as 3.3 million adults in the United States may have ME/CFS and acknowledge that most affected individuals remain undiagnosed (Institute of Medicine, 2015; CDC, 2024). This shift does not mean lupus and ME/CFS should be modeled identically. It does demonstrate that large gaps between older official estimates, advocacy estimates, and later federal estimates are not inherently implausible in high-diagnostic-friction conditions.
The comparison is useful because both illnesses are shaped by delayed recognition, fluctuating symptoms, inconsistent provider familiarity, and dependence on clinicians who understand complex chronic disease patterns. ME/CFS remains more symptom-defined and exclusionary than lupus, while lupus has stronger serologic and specialist-defined pathways; however, both conditions reveal how administrative visibility can lag behind biologic and functional population impact. In ME/CFS, the COVID-19 era made post-infectious chronic illness harder to ignore and helped expose the inadequacy of earlier prevalence assumptions (National Academy of Medicine, 2015; Wirth and Scheibenbogen, 2020). In lupus, post-COVID autoimmune activation may operate differently, but the prevalence systems lesson is similar: lower official counts should be treated as visibility floors, not automatic biological ceilings.
This precedent matters when interpreting the gap between the CDC-funded SLE estimate and the Lupus Foundation of America’s broader lupus estimate. The fact that an advocacy estimate is substantially higher than a strict federal prevalence systems estimate does not, by itself, make the advocacy estimate unreasonable. In chronic immune-mediated conditions, advocacy organizations may observe community-level population impact before federal prevalence systems fully capture it. The ME/CFS example therefore supports a cautious but important principle for lupus prevalence modeling: when a condition is difficult to diagnose, unevenly recognized, and shaped by delayed care pathways, large gaps between formal prevalence systems and broader population impact estimates may be epidemiologically meaningful rather than automatically excessive.
COVID-19, Long COVID, and Autoimmune Disease Risk
The COVID-19 pandemic introduced a new variable into autoimmune disease prevalence systems: the possibility that a large-scale viral event could accelerate immune dysregulation across millions of individuals simultaneously. Although the long-term autoimmune consequences of SARS-CoV-2 infection are still being defined, multiple cohort studies and mechanistic investigations now support an association between COVID-19 and increased risk of autoimmune or immune-mediated disease (Chang et al., 2023; Wang et al., 2023; Gil et al., 2025). These findings are particularly relevant for lupus prevalence modeling because lupus already exists within a diagnostic environment characterized by delayed recognition, fluctuating presentation, and incomplete classification.
COVID accelerated immune dysregulation has been documented across multiple biologic pathways implicated in lupus pathogenesis, including interferon signaling abnormalities, persistent inflammatory activation, autoreactive B-cell expansion, endothelial dysfunction, autoantibody generation, and chronic immune activation (Woodruff et al., 2020; Wang et al., 2021; Su et al., 2022). Several studies have identified elevated rates of antinuclear antibodies, antiphospholipid antibodies, anti-interferon antibodies, and other autoreactive immune signatures following SARS-CoV-2 infection, particularly among patients experiencing prolonged post-viral symptoms (Chang et al., 2023; Wang et al., 2023). Although the presence of autoantibodies alone does not establish lupus, these findings support the broader conclusion that COVID-19 likely increased autoimmune activation pressure across vulnerable populations.
Case reports and observational studies describing new-onset lupus following COVID-19 infection further reinforce this concern. Multiple reports published after 2020 documented patients developing systemic lupus erythematosus or lupus nephritis following SARS-CoV-2 infection, including patients without previously recognized autoimmune disease history (Zamani et al., 2021; Ramachandran et al., 2022). Proposed mechanisms include viral-triggered B-cell activation, interferon dysregulation, molecular mimicry, endothelial injury, and immune-system destabilization in genetically susceptible individuals (Woodruff et al., 2020; Ramachandran et al., 2022). Similar post-viral autoimmune associations have historically been observed following Epstein-Barr virus, hepatitis C, parvovirus, and other infectious triggers linked to lupus-spectrum disease (Tsokos, 2011; Pons-Estel et al., 2010).
Large-scale epidemiologic studies now support a broader autoimmune signal extending beyond isolated case reports. A 2023 EClinical Medicine analysis reported increased risks of multiple autoimmune diseases following COVID-19 infection, including systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s disease, inflammatory bowel disease, and vasculitis (Chang et al., 2023). Additional cohort studies and meta-analyses have similarly identified elevated post-COVID risks for immune-mediated disease development, while emphasizing that the full long-term autoimmune population impact remains incompletely characterized (Wang et al., 2023; Gil et al., 2025). Nature Reviews Rheumatology summarized these findings by noting that SARS-CoV-2 infection appears capable of triggering autoimmune phenomena through multiple overlapping immunologic pathways, though the duration and clinical significance of these effects continue to be investigated (Tesch et al., 2023).
Importantly, these findings do not imply that all Long COVID patients will develop lupus. Nor do they suggest that every post-COVID autoimmune signature represents clinically meaningful lupus-spectrum disease. CYNAERA’s framework instead treats COVID-19 as an upward autoimmune pressure capable of increasing disease activation across genetically and immunologically susceptible populations. The resulting effect on lupus prevalence is therefore likely to be moderate but meaningful rather than explosive or universal.
This distinction becomes particularly important when comparing lupus to conditions such as ME/CFS, dysautonomia, or POTS. Long COVID frequently phenocopies or overlaps these illnesses at high rates, particularly through fatigue, orthostatic intolerance, autonomic instability, neuroinflammation, exertional intolerance, and post-viral symptom persistence (Institute of Medicine, 2015; Wirth and Scheibenbogen, 2020). Lupus conversion is likely narrower because lupus diagnosis remains more dependent on evolving autoimmune pathology, organ-system involvement, serologic patterns, and specialist-confirmed classification. However, even a modest increase in autoimmune activation across a population of hundreds of millions of people may substantially affect long-term lupus-spectrum population impact.
The pandemic may also have intensified undercounting itself. During peak COVID periods, healthcare disruption reduced access to rheumatology care, delayed specialist referrals, interrupted diagnostic testing, and increased barriers to longitudinal follow-up for chronic illness patients. At the same time, post-viral symptoms such as fatigue, neuropathy, inflammatory pain, dysautonomia, rashes, and cognitive dysfunction became more common across the general population. In some patients, these symptoms may ultimately resolve. In others, they may represent evolving autoimmune or connective tissue pathology that remains administratively invisible while disease activity continues biologically. Within the DMM™ framework, COVID-19 therefore functions as both an activation event and a visibility disruptor. It may increase the number of patients entering autoimmune disease trajectories while simultaneously delaying or fragmenting the diagnostic pathways required for formal classification. This creates a prevalence systems environment in which biologic population impact may rise more rapidly than official prevalence estimates are capable of detecting.
Estimating the True U.S. Lupus Population Impact
CYNAERA’s lupus prevalence framework is built around the idea that no single existing estimate fully captures the total population impact of lupus-spectrum disease in the United States. Strict federal prevalence systems estimates, advocacy estimates, registry-based studies, and corrected prevalence models each measure different layers of disease visibility. Rather than treating one estimate as definitively correct and all others as invalid, the DMM™ framework attempts to contextualize how these estimates interact within a high-friction diagnostic environment.
The CDC-funded SLE estimate functions as the strict prevalence systems floor. Using registry-confirmed prevalence systems methods and American College of Rheumatology classification criteria, Izmirly et al. (2021) estimated that approximately 204,295 Americans were living with systemic lupus erythematosus in 2018. This estimate reflects patients successfully captured within formal SLE prevalence systems systems. By design, it prioritizes classification specificity and epidemiologic rigor. However, it does not attempt to estimate the broader lupus-spectrum population that may exist outside registry-confirmed SLE capture.
The Lupus Foundation of America estimates functions differently. The organization currently estimates that approximately 1.5 million Americans have a form of lupus, reflecting a broader lupus-spectrum framing that extends beyond strict SLE registry criteria (Lupus Foundation of America, 2025). This estimate likely captures additional populations including cutaneous lupus, overlap connective tissue disease, incomplete lupus, drug-induced lupus, and individuals clinically recognized as lupus-spectrum patients despite not appearing within strict prevalence systems datasets. The existence of a substantial gap between these estimates suggests that lupus visibility changes dramatically depending on whether prevalence is measured through narrow classification systems or broader clinical-community recognition.
The DMM™ framework models the additional population impact likely hidden between these layers of visibility. The model does not assume that every unexplained inflammatory illness represents lupus, nor does it simply multiply the CDC estimate upward. Instead, CYNAERA uses the 1.5 million advocacy estimate as the broader public population impact anchor, then applies diagnostic-friction logic to account for additional underrecognized disease population impact associated with delayed diagnosis, fluctuating serology, specialist dependency, overlap pathology, post-COVID autoimmune activation, and incomplete classification. This includes patients who may experience clinically meaningful lupus-spectrum disease activity without appearing within formal SLE prevalence systems structures.
Several factors support upward correction pressure within lupus prevalence modeling:
Prolonged diagnostic delay prior to formal classification
Incomplete or evolving lupus presentations
Cutaneous and non-SLE lupus forms
Connective tissue overlap syndromes
Post-COVID autoimmune activation pressure
Specialist-access dependency
Seronegative or fluctuating autoimmune presentations
Misclassification under adjacent inflammatory diagnoses
Underrecognized population impact in male, pediatric, rural, uninsured, and racially underserved populations
Taken together, these factors suggest that current lupus population impact likely extends substantially beyond strict registry-confirmed SLE counts. At the same time, CYNAERA’s framework intentionally avoids unconstrained multiplier expansion. Lupus prevalence correction must remain biologically and epidemiologically plausible. The framework therefore distinguishes between broad lupus-spectrum population impact and strict SLE prevalence rather than collapsing them into a single category. Using this approach, CYNAERA estimates that the current adjusted U.S. lupus population impact is likely closer to approximately 2.5 to 3.0 million people. This estimate represents a corrected lupus-spectrum population impact range rather than a claim that 3 million Americans meet strict SLE classification criteria. The purpose of the estimate is to model the broader population likely affected when diagnostic invisibility, delayed recognition, post-viral autoimmune activation, and incomplete classification are taken into account.
Why the CYNAERA Lupus Estimate Is Innovative
Prevalence correction models are often criticized for the risk of circular reasoning. If a framework begins with the assumption that disease population impact is underestimated, critics may argue that any upward adjustment simply reflects the modeler’s prior belief rather than independently supported evidence. This concern is legitimate and must be addressed directly, particularly in chronic illnesses where prevalence debates have historically become politicized or polarized. The DMM™ framework was designed specifically to reduce this problem by anchoring prevalence correction to externally observable epidemiologic signals rather than arbitrary multiplier expansion.
The model does not begin with a desired final prevalence number. It begins with independent external anchors already present within the literature and public-health landscape. First, federal prevalence systems provide a strict SLE prevalence floor of approximately 204,295 Americans meeting formal classification criteria (Izmirly et al., 2021). Second, the Lupus Foundation of America provides a substantially broader lupus-spectrum estimate of approximately 1.5 million Americans with a form of lupus (Lupus Foundation of America, 2025). Third, diagnostic-delay literature demonstrates that many patients remain biologically ill for years before formal classification occurs (Mitchell et al., 2024). Fourth, post-COVID autoimmune research supports the plausibility of increased autoimmune activation following SARS-CoV-2 infection (Chang et al., 2023; Gil et al., 2025).
The framework therefore does not invent the existence of a prevalence gap. The gap already exists independently within publicly available data. DMM™ attempts to model why the gap exists and how much additional population impact may plausibly remain hidden between strict prevalence systems visibility and broader clinical-community recognition. This distinction is critical. The framework is not claiming that lupus prevalence should increase simply because CYNAERA believes it should. It is argued that measurable features of lupus prevalence systems already suggest substantial compression of visible disease population impact.
Historical precedent further supports this approach. Multiple chronic illnesses characterized by fluctuating symptoms, delayed recognition, and specialist-dependent diagnosis have undergone substantial prevalence reevaluation over time. ME/CFS provides one of the clearest examples. Earlier federal discussions often framed ME/CFS as affecting fewer than 2.5 million Americans, while more recent CDC materials estimate that as many as 3.3 million U.S. adults may have the illness and acknowledge that most patients remain undiagnosed (CDC, 2024; National Academy of Medicine, 2015). Similar visibility expansion has occurred across dysautonomia, hypermobility-associated conditions, mast-cell activation disorders, and post-viral chronic illnesses as awareness, prevalence systems methods, and diagnostic recognition evolved.
This historical pattern does not prove that every chronic illness estimate should be dramatically expanded. However, it demonstrates that diagnosis-based prevalence systems can substantially underestimate conditions characterized by fluctuating symptoms, fragmented care pathways, and delayed specialist recognition. The existence of a large prevalence gap is therefore not inherently evidence of exaggeration. In some cases, it may instead indicate that prevalence systems are capturing only the most administratively visible layer of disease population impact. Within the DMM™ framework, prevalence is treated as both a biologic phenomenon and a systems-visibility phenomenon. A patient who experiences years of inflammatory symptoms, healthcare utilization, functional decline, and autoimmune activity before formal diagnosis still contributes to real disease population impact even if they remain absent from registry-confirmed prevalence datasets. DMM™ attempts to quantify that hidden population impact while remaining anchored to externally observable epidemiologic signals rather than unconstrained theoretical expansion.
Lupus Research, Clinical Trials, and Public Health Impact
If lupus population impact is substantially higher than strict SLE prevalence systems suggest, the implications extend far beyond epidemiologic debate. Prevalence estimates influence nearly every level of healthcare planning, including federal funding allocation, clinical trial recruitment, workforce planning, specialist training, disability forecasting, pharmaceutical investment, and public-health prioritization. When prevalence is compressed, the downstream systems built around those estimates may also become structurally under-scaled.
This issue is particularly important in lupus because the disease already places substantial strain on healthcare systems through chronic management needs, immunosuppressive therapy requirements, hospitalization risk, organ involvement, and long-term disability population impact (Kaul et al., 2016; Fanouriakis et al., 2021). Underestimating prevalence may contribute to insufficient rheumatology capacity, delayed referral networks, inadequate autoimmune screening infrastructure, and reduced investment in therapeutic development. These pressures may become even more significant if post-COVID autoimmune activation increases long-term lupus-spectrum population impact over the coming decade.
The implications are also demographic. Lupus does not affect all populations equally. Registry studies have consistently demonstrated disproportionately elevated lupus prevalence and severity among Black females, Hispanic populations, Asian populations, and American Indian/Alaska Native communities (Lim et al., 2014; Izmirly et al., 2021). Delayed diagnosis and fragmented access to specialty care may further intensify disease population impact in populations already experiencing healthcare inequities. When prevalence systems fail to fully capture these populations, the resulting undercount may influence everything from research prioritization to specialty-clinic distribution and public-health investment.
Clinical trial design may also be affected by compressed prevalence assumptions. Enrollment pipelines, therapeutic targeting strategies, biomarker development programs, and autoimmune drug-market forecasting all depend heavily on assumptions about disease size and visibility. If the lupus-spectrum population is substantially larger than strict SLE prevalence systems suggest, existing research infrastructure may be calibrated to only the most visible subset of patients. This may contribute to therapeutic blind spots, underrepresentation of overlap phenotypes, and insufficient recognition of fluctuating or incomplete disease states. The COVID-19 era adds additional urgency to these concerns. Multiple studies now support increased autoimmune risk following SARS-CoV-2 infection, while Long COVID cohorts continue demonstrating substantial overlap with immune-mediated, autonomic, and inflammatory disease pathways (Chang et al., 2023; Wang et al., 2023; Gil et al., 2025). Even modest increases in autoimmune activation across large populations may significantly affect future rheumatologic population impact. If prevalence systems lag behind biologic reality, healthcare infrastructure may remain persistently underprepared for the scale of long-term autoimmune disease management required in the post-pandemic era.
Prevalence is not merely a statistical exercise. It influences who is believed, who receives specialist attention, which diseases are prioritized, which therapies are funded, and how healthcare systems allocate finite resources. Underestimation therefore carries consequences beyond numbers alone. In chronic illnesses characterized by fluctuating symptoms, delayed diagnosis, and fragmented visibility, prevalence correction may represent not only an epidemiologic adjustment, but a systems-planning necessity.
Conclusion
Lupus prevalence cannot be fully understood through a single prevalence system number alone. The strict federal SLE estimate, the broader advocacy estimate, and corrected prevalence models each capture different layers of disease visibility within a highly complex autoimmune landscape. Registry-confirmed SLE prevalence systems provides an important epidemiologic foundation, but it does not fully account for delayed diagnosis, incomplete lupus presentations, overlap connective tissue disease, fluctuating autoimmune activity, post-viral immune activation, or patients who remain fragmented across healthcare systems without formal classification (Izmirly et al., 2021; Mitchell et al., 2024).
The large gap between the CDC-funded SLE estimate and the Lupus Foundation of America estimate should therefore not automatically be interpreted as implausible or methodologically irresponsible. These estimates are measuring different levels of disease visibility. One captures strict classification-confirmed SLE population impact within formal prevalence systems systems. The other reflects broader lupus-spectrum recognition extending beyond narrow registry definitions (Lupus Foundation of America, 2025). The existence of this discrepancy is itself epidemiologically meaningful because it demonstrates how dramatically disease population impact can shift depending on how visibility is defined. The COVID-19 pandemic further complicates lupus prevalence modeling by introducing large-scale post-viral autoimmune pressure into an already underrecognized disease environment. Multiple cohort studies and mechanistic investigations now support increased risks of autoimmune activation following SARS-CoV-2 infection, including elevated risks for lupus-spectrum disease pathways (Chang et al., 2023; Wang et al., 2023; Gil et al., 2025). Although current evidence does not support the conclusion that all Long COVID patients develop lupus, it strongly suggests that autoimmune population impact may be increasing more rapidly than traditional prevalence systems are capable of detecting.
The CYNAERA Diagnostic Multiplier™ Model™ was developed to address this visibility gap. Rather than treating prevalence as a fixed administrative count, DMM™ models prevalence as a systems-dependent variable shaped by diagnostic timing, specialist access, classification structure, healthcare visibility, and disease complexity. The framework does not attempt to replace traditional epidemiology, nor does it assume that every unexplained inflammatory illness represents lupus. Instead, it attempts to quantify how much biologically meaningful disease population impact may remain hidden between strict prevalence systems visibility and broader clinical reality.
Using existing federal and advocacy prevalence anchors, alongside literature on diagnostic delay, autoimmune activation, and chronic illness under-recognition, CYNAERA estimates that the current adjusted U.S. lupus population impact is likely closer to approximately 2.5 to 3.0 million people. This estimate should be interpreted as a corrected lupus-spectrum population impact range rather than a claim that all affected individuals meet strict SLE classification criteria. Its purpose is to support more accurate long-term planning for autoimmune prevalence systems, therapeutic development, specialist workforce needs, clinical-trial infrastructure, and post-COVID chronic illness preparedness.
Ultimately, prevalence estimates shape more than epidemiologic reports. They influence funding allocation, healthcare infrastructure, therapeutic investment, public-health prioritization, disability planning, and the visibility of the populations most affected by chronic illness. In diseases characterized by delayed recognition and fragmented diagnostic pathways, the difference between visible population impact and true population impact may be substantial. Lupus prevalence modeling must therefore evolve beyond narrow registry capture toward frameworks capable of accounting for the biologic and systems level realities shaping modern autoimmune disease. This framework is further informed by The Eve Research Project, an ongoing, multi-phase research program examining how autoimmune symptoms evolve across hormonal life stages, environmental exposures, and flare patterns.
Lupus Prevalence Frequently Asked Questions
Does CYNAERA claim that 3 million Americans have formally diagnosed SLE?
No. The CYNAERA estimate refers to broader lupus-spectrum population impact, not strictly registry-confirmed systemic lupus erythematosus. The estimate includes the likelihood of underrecognized, delayed, incomplete, overlap, and administratively invisible lupus-spectrum disease population impact beyond formal SLE prevalence systems systems.
Why is the CYNAERA estimate higher than CDC prevalence systems estimates?
The CDC-funded estimate measures patients meeting strict SLE classification criteria within registry confirmed prevalence systems frameworks (Izmirly et al., 2021). CYNAERA’s framework models additional disease population impact associated with diagnostic delay, fluctuating presentation, specialist dependency, incomplete lupus, and COVID accelerated autoimmune activation.
Is the 1.5 million Lupus Foundation estimate already accounting for underdiagnosis?
Partially. The Lupus Foundation estimate appears to reflect broader lupus-spectrum population impact beyond strict SLE classification. CYNAERA treats this estimate as a broader public population impact anchor rather than a strict prevalence systems count. The DMM™ framework models additional population impact likely hidden beyond both formal prevalence systems and advocacy visibility.
Does COVID-19 cause lupus?
Current evidence does not support the conclusion that SARS-CoV-2 universally causes lupus. However, multiple studies suggest COVID-19 may increase autoimmune activation risk in susceptible individuals and may contribute to new onset autoimmune disease in a subset of patients (Chang et al., 2023; Gil et al., 2025).
Why compare lupus to ME/CFS?
ME/CFS provides an important prevalence systems precedent. Both illnesses involve delayed diagnosis, fluctuating symptoms, specialist-dependent recognition, and substantial evidence of historical undercounting. The pandemic accelerated expansion of ME/CFS prevalence estimates demonstrates how chronic illnesses can remain compressed within official prevalence systems for extended periods.
Does DMM™ replace traditional epidemiology?
No. DMM™ is designed to complement traditional prevalence methods by modeling diagnostic visibility limitations in high-friction chronic illnesses. It does not replace registry prevalence systems, classification studies, or biomarker-based epidemiology.
What is meant by “lupus-spectrum population impact”?
Lupus-spectrum population impact includes patients with systemic lupus erythematosus as well as patients with incomplete lupus, overlap connective tissue disease, cutaneous lupus, evolving autoimmune presentations, and related inflammatory disease states that may not yet appear within strict registry-confirmed SLE prevalence systems.
Why does diagnostic delay matter for prevalence modeling?
Patients remain biologically and functionally ill before formal diagnosis occurs. In lupus, diagnostic delays may extend across multiple years (Mitchell et al., 2024). Prevalence systems based only on confirmed diagnosis may therefore compress the true duration and population impact of disease activity.
Appendix A: Lupus State Estimates, SVT Tier & Methodology
The SVT (Systems Vulnerability Tier™) framework is a CYNAERA state-level calibration system used to estimate how environmental load, healthcare access, demographic composition, chronic disease burden, pollution exposure, and diagnostic visibility may influence autoimmune prevalence and disease recognition across the United States. Rather than assuming lupus prevalence is evenly distributed nationally, the framework models how cumulative systems stress may increase or suppress visible disease burden at the state level.
SVT tiers are defined as:
Tier 1 = highest projected cumulative autoimmune load and visibility-adjusted burden
Tier 2 = moderate-to-high projected burden
Tier 3 = lower projected burden or lower visibility-adjusted risk
The lupus estimates shown above are not strict systemic lupus erythematosus (SLE) surveillance counts alone. They are CYNAERA lupus-spectrum estimates generated using a visibility-adjusted modeling approach integrating:
state population size
racial and ethnic demographics
published SLE prevalence patterns
environmental exposure burden
healthcare access variability
diagnostic visibility patterns
specialist access
post-COVID autoimmune pressure
and overlap lupus-spectrum conditions
The model incorporates principles from:
US-CCUC™ (U.S. Chronic Condition Undercount Correction)
DMM™ (Diagnostic Multiplier™ Model™)
DVC™ (Diagnostic Visibility Coefficient™)
and SFI™ (Stereotype Fit Index™)
These estimates are intended as planning and systems-burden projections rather than exact confirmed case counts.
State | SVT Tier | Lupus Estimated Range |
Alabama | 2 | 34,318–41,181 |
Alaska | 3 | 4,517–5,421 |
Arizona | 2 | 51,417–61,701 |
Arkansas | 2 | 23,889–28,667 |
California | 1 | 301,536–361,844 |
Colorado | 2 | 41,147–49,376 |
Connecticut | 3 | 22,915–27,498 |
Delaware | 2 | 7,171–8,605 |
Florida | 1 | 167,936–201,523 |
Georgia | 2 | 76,838–92,205 |
Hawaii | 2 | 19,920–23,904 |
Idaho | 3 | 13,088–15,706 |
Illinois | 2 | 88,529–106,235 |
Indiana | 2 | 47,718–57,262 |
Iowa | 3 | 20,359–24,431 |
Kansas | 3 | 19,766–23,719 |
Kentucky | 2 | 31,349–37,619 |
Louisiana | 2 | 31,293–37,552 |
Maine | 3 | 17,096–20,515 |
Maryland | 2 | 45,149–54,179 |
Massachusetts | 3 | 22,464–26,957 |
Michigan | 2 | 71,287–85,545 |
Minnesota | 3 | 37,899–45,479 |
Mississippi | 2 | 20,297–24,356 |
Missouri | 2 | 43,171–51,805 |
Montana | 3 | 7,503–9,004 |
Nebraska | 3 | 13,088–15,706 |
Nevada | 2 | 23,546–28,255 |
New Hampshire | 3 | 17,874–21,449 |
New Jersey | 2 | 65,180–78,216 |
New Mexico | 2 | 14,581–17,497 |
New York | 2 | 134,631–161,558 |
North Carolina | 2 | 86,178–103,413 |
North Dakota | 3 | 5,226–6,272 |
Ohio | 2 | 99,312–119,175 |
Oklahoma | 2 | 28,602–34,323 |
Oregon | 2 | 29,897–35,876 |
Pennsylvania | 2 | 111,003–133,203 |
Rhode Island | 3 | 13,533–16,239 |
South Carolina | 2 | 43,263–51,916 |
South Dakota | 3 | 6,040–7,248 |
Tennessee | 2 | 56,454–67,745 |
Texas | 1 | 222,782–267,338 |
Utah | 3 | 25,458–30,550 |
Vermont | 3 | 8,517–10,221 |
Virginia | 2 | 68,930–82,716 |
Washington | 2 | 66,845–80,214 |
West Virginia | 3 | 11,571–13,885 |
Wisconsin | 3 | 37,360–44,832 |
Wyoming | 3 | 3,776–4,531 |
Appendix B: Race By State Lupus Prevalence Calibration
Race by state modeling should not imply that race itself causes lupus. It estimates how ancestry-linked risk, environmental exposure, healthcare access, diagnostic visibility, and state-level infrastructure interact to shape measured and hidden lupus prevalence.
Methodology Note
These estimates were generated using CYNAERA visibility adjusted prevalence modeling integrating:
published SLE prevalence disparities
race-adjusted lupus-spectrum correction logic
state demographic distribution
post-COVID autoimmune pressure
and US-CCUC™ / DMM™ visibility calibration methods
These estimates represent projected lupus spectrum population impact rather than strict confirmed SLE surveillance counts.
State | White | Black | Latine | Asian/PI | AI/AN | Total |
Alabama | 14,000–17,000 | 13,000–17,000 | 2,000–3,000 | 800–1,200 | 300–700 | 34,318–41,181 |
Alaska | 2,000–2,400 | 200–400 | 300–500 | 300–500 | 1,200–1,700 | 4,517–5,421 |
Arizona | 24,000–29,000 | 4,000–6,000 | 15,000–19,000 | 5,000–7,000 | 3,000–5,000 | 51,417–61,701 |
Arkansas | 13,000–15,000 | 7,000–9,000 | 1,000–2,000 | 500–900 | 300–700 | 23,889–28,667 |
California | 92,000–108,000 | 38,000–49,000 | 88,000–112,000 | 48,000–62,000 | 3,500–5,000 | 301,536–361,844 |
Colorado | 25,000–30,000 | 2,000–4,000 | 8,000–11,000 | 3,000–5,000 | 2,000–3,000 | 41,147–49,376 |
Connecticut | 14,000–17,000 | 4,000–6,000 | 3,000–4,000 | 1,500–2,500 | 300–700 | 22,915–27,498 |
Delaware | 3,000–4,000 | 2,000–3,000 | 800–1,200 | 300–500 | 100–300 | 7,171–8,605 |
Florida | 82,000–97,000 | 34,000–43,000 | 32,000–41,000 | 8,000–11,000 | 1,500–2,500 | 167,936–201,523 |
Georgia | 28,000–33,000 | 28,000–36,000 | 9,000–13,000 | 4,000–6,000 | 500–1,000 | 76,838–92,205 |
Hawaii | 4,000–5,000 | 300–700 | 2,000–3,000 | 11,000–14,000 | 500–1,000 | 19,920–23,904 |
Idaho | 11,000–13,000 | 200–400 | 1,000–2,000 | 500–900 | 500–1,000 | 13,088–15,706 |
Illinois | 39,000–46,000 | 22,000–28,000 | 16,000–21,000 | 8,000–11,000 | 700–1,200 | 88,529–106,235 |
Indiana | 31,000–37,000 | 9,000–12,000 | 3,000–5,000 | 2,000–3,000 | 500–1,000 | 47,718–57,262 |
Iowa | 17,000–20,000 | 1,000–2,000 | 1,000–2,000 | 800–1,200 | 300–700 | 20,359–24,431 |
Kansas | 13,000–16,000 | 2,000–3,000 | 3,000–5,000 | 1,000–2,000 | 500–900 | 19,766–23,719 |
Kentucky | 24,000–28,000 | 5,000–7,000 | 1,000–2,000 | 800–1,200 | 300–700 | 31,349–37,619 |
Louisiana | 10,000–12,000 | 15,000–19,000 | 3,000–5,000 | 1,000–2,000 | 300–700 | 31,293–37,552 |
Maine | 15,000–18,000 | 300–700 | 500–900 | 500–900 | 300–700 | 17,096–20,515 |
Maryland | 16,000–19,000 | 16,000–21,000 | 6,000–8,000 | 5,000–7,000 | 300–700 | 45,149–54,179 |
Massachusetts | 16,000–19,000 | 3,000–5,000 | 3,000–5,000 | 2,000–3,000 | 300–700 | 22,464–26,957 |
Michigan | 34,000–40,000 | 24,000–31,000 | 6,000–9,000 | 4,000–6,000 | 700–1,200 | 71,287–85,545 |
Minnesota | 29,000–34,000 | 3,000–5,000 | 3,000–5,000 | 2,000–3,000 | 700–1,200 | 37,899–45,479 |
Mississippi | 7,000–9,000 | 10,000–13,000 | 1,000–2,000 | 400–800 | 200–500 | 20,297–24,356 |
Missouri | 28,000–33,000 | 10,000–13,000 | 2,000–3,000 | 1,000–2,000 | 500–900 | 43,171–51,805 |
Montana | 5,000–6,000 | 100–300 | 300–500 | 200–400 | 1,500–2,500 | 7,503–9,004 |
Nebraska | 10,000–12,000 | 1,000–2,000 | 1,000–2,000 | 800–1,200 | 300–700 | 13,088–15,706 |
Nevada | 10,000–12,000 | 3,000–5,000 | 7,000–9,000 | 2,000–3,000 | 500–900 | 23,546–28,255 |
New Hampshire | 15,000–18,000 | 300–700 | 500–900 | 500–900 | 300–700 | 17,874–21,449 |
New Jersey | 26,000–31,000 | 18,000–23,000 | 13,000–18,000 | 7,000–10,000 | 300–700 | 65,180–78,216 |
New Mexico | 5,000–7,000 | 300–700 | 7,000–9,000 | 300–700 | 2,000–3,000 | 14,581–17,497 |
New York | 48,000–57,000 | 32,000–40,000 | 34,000–44,000 | 16,000–22,000 | 1,000–1,800 | 134,631–161,558 |
North Carolina | 34,000–41,000 | 28,000–35,000 | 10,000–14,000 | 4,000–6,000 | 500–1,000 | 86,178–103,413 |
North Dakota | 4,000–5,000 | 100–300 | 300–500 | 200–400 | 500–900 | 5,226–6,272 |
Ohio | 56,000–66,000 | 24,000–30,000 | 8,000–11,000 | 5,000–7,000 | 500–1,200 | 99,312–119,175 |
Oklahoma | 12,000–14,000 | 4,000–6,000 | 3,000–5,000 | 1,000–2,000 | 6,000–8,000 | 28,602–34,323 |
Oregon | 22,000–26,000 | 1,000–2,000 | 4,000–6,000 | 2,000–3,000 | 500–1,000 | 29,897–35,876 |
Pennsylvania | 58,000–68,000 | 22,000–28,000 | 12,000–16,000 | 7,000–10,000 | 800–1,500 | 111,003–133,203 |
Rhode Island | 8,000–10,000 | 2,000–3,000 | 1,000–2,000 | 500–900 | 100–300 | 13,533–16,239 |
South Carolina | 15,000–18,000 | 18,000–23,000 | 2,000–3,000 | 1,000–2,000 | 300–700 | 43,263–51,916 |
South Dakota | 4,000–5,000 | 100–300 | 300–500 | 200–400 | 1,000–2,000 | 6,040–7,248 |
Tennessee | 27,000–32,000 | 16,000–21,000 | 3,000–5,000 | 2,000–3,000 | 500–900 | 56,454–67,745 |
Texas | 70,000–84,000 | 36,000–46,000 | 82,000–106,000 | 18,000–24,000 | 2,500–4,000 | 222,782–267,338 |
Utah | 18,000–21,000 | 300–700 | 3,000–5,000 | 2,000–3,000 | 1,000–2,000 | 25,458–30,550 |
Vermont | 7,000–8,000 | 100–300 | 200–400 | 200–400 | 100–300 | 8,517–10,221 |
Virginia | 29,000–34,000 | 18,000–23,000 | 9,000–12,000 | 8,000–11,000 | 500–1,000 | 68,930–82,716 |
Washington | 33,000–39,000 | 3,000–5,000 | 8,000–11,000 | 12,000–16,000 | 1,000–2,000 | 66,845–80,214 |
West Virginia | 10,000–12,000 | 500–900 | 300–500 | 200–400 | 100–300 | 11,571–13,885 |
Wisconsin | 29,000–34,000 | 3,000–5,000 | 2,000–3,000 | 2,000–3,000 | 700–1,200 | 37,360–44,832 |
Wyoming | 2,000–3,000 | 100–300 | 300–500 | 100–300 | 500–900 | 3,776–4,531 |
How to Cite This Paper
Adinig, C. (2026). The Hidden Prevalence of Lupus in the U.S. CYNAERA. Available at: https://www.cynaera.com/post/lupus-prevalence
CYNAERA Framework Papers and Core Research Libraries
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
CDC. (2024). About Lupus. Centers for Disease Control and Prevention.
CDC. (2024). Fast Facts About ME/CFS. Centers for Disease Control and Prevention.
Chang, R., Yen-Ting, H., Chang, W. et al. (2023). Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. EClinicalMedicine, 56, 101783.
Durcan, L., O’Dwyer, T. and Petri, M. (2019). Management strategies and future directions for systemic lupus erythematosus in adults. The Lancet, 393(10188), pp.2332–2343.
Fanouriakis, A., Kostopoulou, M., Alunno, A. et al. (2021). 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 80(1), pp.14–25.
Gil, A.M., Santos, M.J. and Silva, C. et al. (2025). Risk of immune-mediated diseases after SARS-CoV-2 infection: Systematic review and meta-analysis. Autoimmunity Reviews, 24(1).
Institute of Medicine. (2015). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: National Academies Press.
Izmirly, P.M., Parton, H., Wang, L. et al. (2021). Prevalence of systemic lupus erythematosus in the United States: Estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis & Rheumatology, 73(6), pp.991–996.
Kaul, A., Gordon, C., Crow, M.K. et al. (2016). Systemic lupus erythematosus. Nature Reviews Disease Primers, 2, 16039.
Lim, S.S., Drenkard, C., McCune, W.J. et al. (2014). Population-based lupus registries: Advancing epidemiology and understanding health disparities. Arthritis & Rheumatology, 66(11), pp.2932–2940.
Lupus Foundation of America. (2025). Lupus Facts and Statistics. Lupus Foundation of America.
Mitchell, J.L., Trupin, L., Yazdany, J. et al. (2024). Understanding the impact of delayed diagnosis and misdiagnosis in systemic lupus erythematosus. Lupus Science & Medicine, 11(1).
National Academy of Medicine. (2015). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: National Academies Press.
Pisetsky, D.S. (2023). Antinuclear antibodies in systemic lupus erythematosus. Nature Reviews Rheumatology, 19, pp.485–497.
Pons-Estel, G.J., Alarcón, G.S., Scofield, L. et al. (2010). Understanding the epidemiology and progression of systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 39(4), pp.257–268.
Ramachandran, L., Dontaraju, V.S., Troyer, J. and Sahota, J. (2022). New onset systemic lupus erythematosus after COVID-19 infection: A case report. AME Case Reports, 6, 14.
Rees, F., Doherty, M., Grainge, M.J. et al. (2017). The worldwide incidence and prevalence of systemic lupus erythematosus: A systematic review of epidemiological studies. Rheumatology, 56(11), pp.1945–1961.
Smolen, J.S., Aletaha, D. and McInnes, I.B. (2020). Rheumatoid arthritis and related autoimmune inflammatory disease mechanisms. The Lancet, 388(10055), pp.2023–2038.
Su, Y., Yuan, D., Chen, D.G. et al. (2022). Multiple early factors anticipate post-acute COVID-19 sequelae. Cell, 185(5), pp.881–895.
Tesch, S., Manger, B. and Schett, G. (2023). Autoimmunity after COVID-19. Nature Reviews Rheumatology, 19, pp.9–10.
Tsokos, G.C. (2011). Systemic lupus erythematosus. New England Journal of Medicine, 365(22), pp.2110–2121.
Wang, E.Y., Mao, T., Klein, J. et al. (2021). Diverse functional autoantibodies in patients with COVID-19. Nature, 595, pp.283–288.
Wang, L., Foer, D., MacPhaul, E. et al. (2023). Association of COVID-19 with short- and long-term risk of autoimmune and autoinflammatory connective tissue disorders. JAMA Network Open, 6(10).
Wirth, K. and Scheibenbogen, C. (2020). Pathophysiology of skeletal muscle disturbances in ME/CFS. Journal of Translational Medicine, 18, 162.
Comments